Design and Implementation of Improved SARS-CoV-2 Diagnostic Assays To Mitigate the Impact of Genomic Mutations on Target Failure: the Xpert Xpress SARS-CoV-2 Experience

In 2020, the U.S. Food and Drug Administration (FDA) enabled manufacturers to request emergency use authorization (EUA) to facilitate the rapid authorization of in vitro diagnostic (IVD) platforms for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Uncommon SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Burns, Bethany L., Moody, Domonique, Tu, Zheng Jin, Nakitandwe, Joy, Brock, Jay E., Bosler, David, Mitchell, Stephanie L., Loeffelholz, Michael J., Rhoads, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769917/
https://www.ncbi.nlm.nih.gov/pubmed/36255326
http://dx.doi.org/10.1128/spectrum.01355-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769917/
https://www.ncbi.nlm.nih.gov/pubmed/36255326
http://dx.doi.org/10.1128/spectrum.01355-22

Ejemplares similares